Eli Lilly forges $1B diabetes deal

Eli Lilly is putting down a $41 million payment to acquire exclusive rights to MacroGenics' diabetes drug teplizumab in a deal that could be worth more than a billion dollars in total. MacroGenics also gets a $10 million financing arrangement, up to $200 million in development milestones for diabetes, sales milestones of $250 million and up to $600 million for other approvals of molecules developed by the two companies. For MacroGenics, the deal with Lilly marks a key turning point as it develops new therapies for cancer, autoimmune diseases and infectious diseases. Teplizumab is its lead therapy and marks Eli Lilly's continued interest in acquiring more biotech drugs for development.

"The additional capital brought into the company will give us the ability to expand our portfolio and work in other areas," MacroGenics chief executive Dr. Scott Koenig told the Baltimore Sun said in an interview.

- take a look at the release on the deal
- read the Baltimore Sun's report

Related Articles:
Lilly diabetes med linked to pancreatitis. Report
MacroGenics garners $45M in third round. Report
In speech, Lilly CEO calls for drug monitoring. Report
Lilly developing biotech drugs the old-fashioned way. Report
Diabetes epidemic triggers soaring drug market. Report

Read more on: Eli Lilly | Diabetes

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.